A5058471652- Sarcoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Medical Imaging and Pathology Studies
- Lung Cancer Treatments and Mutations
- Advanced Radiotherapy Techniques
- Renal and related cancers
- Cardiac, Anesthesia and Surgical Outcomes
- Social Media in Health Education
- Bone Tumor Diagnosis and Treatments
- Cardiac Imaging and Diagnostics
- Tuberous Sclerosis Complex Research
- Soft tissue tumor case studies
- Lymphoma Diagnosis and Treatment
- Sepsis Diagnosis and Treatment
- Frailty in Older Adults
- CAR-T cell therapy research
- Economic and Financial Impacts of Cancer
- Musculoskeletal synovial abnormalities and treatments
- Vascular Tumors and Angiosarcomas
- Gastrointestinal Tumor Research and Treatment
Institut de Cancérologie Strasbourg
2021-2025
510 Background: Lenvatinib-based therapy has shown efficacy in the frontline treatment of metastatic renal cell carcinoma (mRCC). However, there is uncertainty about role Lenvatinib (LEN) subsequent lines treatment, particularly after immune checkpoint inhibitors (ICI) and tyrosine kinase (TKI). This study aimed to describe real-world clinical outcomes patients (pts) with mRCC treated LEN-based therapies beyond first-line treatment. Methods: Retrospective multicenter including all pts at...
Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little known about immune checkpoint inhibitor activity in central nervous system, especially patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted GFPC, included treatment-naïve strongly positive PD-L1 (TPS 50%) BM first-line single-agent pembrolizumab treatment between May 2017 and November 2019. The primary...
Introduction: Cancer patients are at high risk of developing septic shock (SSh) and increasingly admitted to ICU given their improved long-term prognosis. We, therefore, compared the prognosis cancer non-cancer with SSh. Methods: We conducted a monocentric, retrospective cohort study (2013–2019) on for clinical characteristics management studied short- mortality in-hospital 1-year survival according status. Results: analyzed 239 stays in 210 patients, 59.5% whom were men (n = 125), median...
In the era of immune checkpoint inhibitors (ICI), managing non-oncogene driven non-small cell lung cancer (NSCLC) with brain metastases (BM) is challenging, especially when involvement initial sign. Patients newly diagnosed metastatic NSCLC without epidermal growth factor receptor (EFGR) nor anaplastic lymphoma kinase (ALK) alterations were retrospectively included. Twenty-five patients analyzed; 15 (60%) had symptomatic BM as first sign (group 1), while 10 (40%) discovered during...
According to guidelines, all patients with sarcoma must be managed from initial diagnosis at expert centers. However, in everyday practice, the time interval an center visit can long, which delays presentation multidisciplinary tumor board and increases risk of inappropriate management, negatively affecting local control prognosis. The advent mobile health offers easy way facilitate communication cooperation between general care providers (eg, practitioners radiologists) sarcomas experts. We...
<sec> <title>BACKGROUND</title> According to guidelines, all sarcoma patients must be managed from initial diagnosis at expert centers. However, in everyday practice, the time interval an center visit can long, which delays presentation multidisciplinary tumor board (MTB) and increases risk of inappropriate management, negatively affecting local control prognosis. The advent mobile health (mHealth) offers easy way facilitate communication cooperation between general care providers (e.g.,...